Our Network of Consultants

Senior Molecular Biologist with 35+ Years of International Experience (Europe/USA)
Expertise: Gene Therapy (rAAV & Lentiviral Vectors), Synthetic Biology, Molecular Biology, Biochemistry, and Cell Biology across Mammalian, Bacterial, Yeast, and Plant Systems
 Specialised in:
- Advanced Vector Engineering: Design and validation of custom plasmids for specific in vivo and in vitro assay requirements; expression cassette engineering by selecting promoters, enhancers, regulatory elements, and seqeunce optimisation (species-tissue optimisation); tailoring of cloning and assembly methods and validation; safety and manufacturability.
- Construct Stability: Troubleshooting DNA instability challenges such as repeated sequences, ITR, GC-rich sequences, and gene toxicity.
- Regulatory Practices: Design of GMP-compliant workflows, documentation, and manufacturing alignment.

My area of study is the intersection of clinical neuroscience, translational pharmacology, and computational biomarker discovery. I am a PhD candidate investigating how glymphatic and meningeal–lymphatic pathways relate to neuroinflammation in humans. I focus on immune-cell phenotyping and cell-free markers that may index inflammatory activity and neurodegenerative trajectories. Alongside sampling development, I contribute to assay and workflow optimisation for mass-spectrometry-ready proteomics, with an emphasis on automation, quality control, and reproducibility.

My pharmacology and drug-safety foundation was built through an MRes in Biological Science and Translational Medicine. I examined dose- and time-dependent paracetamol-induced kidney injury in renal cell models, differentiating apoptotic and necrotic mechanisms and linking experimental readouts to clinically relevant nephrotoxicity questions. I completed a systematic review on cilastatin as a renoprotective strategy and critically evaluated in vitro acute kidney injury models for translational validity. I also gained ward-level exposure as a Clinical Research Associate in nephrology, aligning laboratory findings with real-world clinical pathways and multidisciplinary decision-making.

From an industry and communications perspective, I have experience in medical affairs-adjacent work, including market analysis to support launch planning in an ophthalmic pharmaceutical company and the development of compliant training materials with medical teams. I have delivered conference and hospital presentations, tailoring complex findings to both clinical and public audiences, and I have completed structured projects on European compliance frameworks, which underpins my approach to regulatorily aware medical writing.

Computationally, I build end-to-end machine-learning workflows in Python and R for noisy, high-dimensional datasets, particularly proteomics and multimodal clinical data. My toolkit spans supervised learning, unsupervised clustering, and dimensionality reduction.

Overall, my expertise is translating complex biomedical and quantitative evidence into actionable deliverables, supported by an MBA in Clinical Leadership and a strong biochemistry foundation, including earlier research on TEX12 expression in somatic and cancer models.

Physician | Clinical Scientist | Vaccine & Biologics Development

Physician and clinical scientist with over 15 years of international experience across the full spectrum of vaccine and biologics development, from early-phase innovation to late-phase clinical implementation. Currently serving as Clinical Science Lead at GSK Vaccines (Italy), providing strategic and scientific leadership for late-phase clinical trials in meningococcal disease and other vaccine-preventable infections.

My professional background includes early clinical development programs addressing antimicrobial resistance and neglected tropical diseases, with hands-on experience in monoclonal antibodies and innovative delivery strategies. I have contributed to more than 40 clinical trials across Latin America, Europe, and complex or conflict-affected settings, including investigator-initiated studies, the establishment of clinical research centers, and collaborations with global health organizations such as WHO and DNDi.

I hold formal training in epidemiology and global health, with solid regulatory experience interacting with FDA, EMA, and WHO frameworks. My work is guided by scientific rigor, operational excellence, and a strong commitment to public health impact.

I am particularly interested in the intersection of clinical development, data science, and digital innovation to improve clinical decision-making in immunology and translational medicine. I value cross-functional collaboration, ethical leadership, and mission-driven science, and I am always open to scientific exchange and global partnerships that advance equitable access to transformative health solutions.

During 16 years as a Ph.D. immunologist in the Life Science sector, I gained extensive expertise in the areas of inflammation/autoimmunity, immuno-oncology, MicroRNA therapeutics as well as vaccine platforms. I established a long-standing track record in lead identification and biomarker discovery work.

Working in the small-biotech environment, I embraced an entrepreneurial mindset and the necessity of wearing multiple hats across R&D, quickly adapting to an agile, fast-paced atmosphere to drive early-stage innovation. This hands-on approach and broad exposure to various functions, offered me a holistic view of the pipeline and the direct impact of my work. Transitioning to the corporate environment of a world-leading pharmaceutical company, I was able to utilize my diverse background while benefiting from the processes, resources, and expertise that define large organizations. In this highly impactful system, I was fortunate to lead and contributed to large-scale, international, high-priority projects with my work being instrumental to achieve set milestones.

As a consultant, I will be able to support activities across the full spectrum of the R&D pipeline, including, but not limited to:
• Identifying innovative new therapeutic concepts for immunological indications and pipeline expansion
• Developing mechanistic- and unmet-need-based research strategy to advance characterization of therapeutic targets and biomarkers
• Spearheading the development of novel in-vivo and ex-vivo animal and pathway models
• Supporting and guiding laboratory-based scientists in planning, execution and data analysis of in-vitro and in-vivo studies
• Bridging cross-functional/translational work with internal stakeholders as well as key external experts

KEY STRENGTH AND SKILLS
• Extensive expertise in early-to late-stage immunological research in the context of immuno-oncology and inflammation/autoimmunity
• Highly experienced in working cross functional within global project teams and with external partners/CROs
• Leadership experience by managing and mentoring teams and individual scientists
• Deep knowledge in cell- and molecular biology (with a vast array of in-vitro and in-vivo immune-bioassays), as well as characterization of disease relevant signaling pathways
• Extensive background in various animal models and multiple species
• Highly proficient in data analysis, -management, and -interpretation
• Excellent verbal and written communication- and presentation skills

I am a freelance Quality Assurance consultant/auditor with 14 years experience in the Pharmaceutical industry and I offer QMS development/support and Lead Auditor services for Life Science and Biotech organisations. My most recent role prior to freelance work was as the Global Supplier Quality Manager for a Biotech organisation where I was responsible for management of over 100 suppliers, with oversight of a small team of auditors and conduct of audits as a Lead Auditor in support for Clinical operations, as well as development/support for the site QMS.

With over 14 years of experience in the biotechnology and pharmaceutical sectors, I have established myself as a dynamic and results-driven leader, excelling in roles that demand strategic vision, scientific acumen, and exceptional project management skills. My career has been marked by significant contributions to drug discovery, innovation management, and business development, with a proven track record of driving growth and fostering client loyalty.

As Chief Business Officer in a CRO, I spearheaded business development initiatives, proactively engaging potential clients through targeted outreach campaigns. I successfully managed the entire sales cycle and secured contracts with biotech and major pharmaceutical companies. My ability to develop comprehensive proposals, aligning technical and financial aspects with client needs, ensured effective project management and client satisfaction. I represented the company's key assets at international congresses, further enhancing our market presence.

In my concurrent role as Chief Innovation Officer, I secured substantial funding for R&D projects through programs like Eurostar. My expertise in providing scientific and technical guidance to stakeholders has been instrumental in driving innovation and maintaining high standards of project execution.

Prior to these roles, as Chief Project Officer, I spearheaded drug discovery research projects, evaluating the efficacy, mechanism of action, and proof of concept for various candidates, including viruses, antibodies, small molecules, and vaccines. I managed cross-functional teams, budgets, timelines, and deliverables, ensuring project completion and regulatory compliance. My ability to analyze data and my deep expertise in flow cytometry, in vitro assays, immunology, mouse models and preclinical pharmacology evaluation allowed me to present comprehensive reports to clients and ensure project success and client satisfaction.

My academic foundation includes a PhD in immuno-oncology and a tenure as a Research Scientist at INSERM. I secured two post-doctoral grants and authored several peer-reviewed publications, further solidifying my scientific expertise.

Throughout my career, I have demonstrated a strong commitment to leadership, team collaboration, and client-centric approaches. My ability to fuse scientific knowledge with strategic business acumen has enabled me to drive impactful projects and foster long-term client relationships. I am eager to bring this unique blend of skills and experiences to new challenges, continuing to innovate and deliver exceptional results in the biotechnology and pharmaceutical sectors.

As a strategic life sciences leader with over 14 years of experience in oncology, immuno-oncology, and cell and gene therapy, I am passionate about advancing innovative therapies that improve patient outcomes. My journey in biotech has been defined by a hands-on approach to discovery research, product development, and regulatory strategy, taking concepts from the lab bench to clinical trials.

Throughout my career, I’ve had the privilege of leading and contributing to groundbreaking projects. At TC BioPharm, I played a pivotal role in the FDA approval of an allogeneic gamma delta T cell therapy and the preclinical development of next-generation CAR-T products. My expertise in developing complex assays and driving exploratory clinical analyses has been critical in achieving key milestones, including advancing a phase 2/3 AML clinical trial.

As a consultant, I leverage my experience to guide biotech companies in refining development strategies and bridging preclinical and clinical efforts. From conducting due diligence for investments to streamlining development pathways, I provide actionable insights that reduce timelines and costs while maintaining scientific and regulatory rigour.
Collaboration is at the heart of this effort. I thrive in cross-functional teams, ensuring seamless integration across R&D, clinical, regulatory, and manufacturing functions. I also enjoy mentoring, developing talent, and fostering team innovation and resilience.

I actively contribute to the scientific community, having presented at international conferences such as the Gamma Delta T Cell Therapies Summit and the Allogeneic Cell Therapies Summit. My academic foundation, with a PhD in Medicine from the University of Glasgow, further underpins my technical expertise and commitment to translating research into impactful therapies.

Joining this network aligns with my drive to connect with like-minded professionals with a vision for transforming healthcare. I am eager to contribute my knowledge, learn from peers, and explore opportunities for collaboration that can accelerate therapeutic development and benefit patients worldwide.

Senior Life Sciences Executive and Technical Expert with 15+ years of experience driving innovation in biotechnology. Proven track record in building and scaling successful ventures, specializing in cell biology, automation, and AI-powered solutions. Currently serving as CEO of an iPSC technology company, while offering strategic consulting to emerging life science ventures.

Technical Expertise:
- Cell culture and cell line development (CLD)
- Extensive experience with cancer, CHO, HEK, cultured meat and iPSC cell lines
- Developing and validating automation and high-throughput AI-based imaging instrumentation
- Cell line optimization, immortalisation, engineering and characterization

Molecular & Synthetic Biology:
- Gene editing and genetic engineering
- Vector design and production
- Protein expression systems

Leadership Experience:
- Founded and scaled an iPSC quality control company from concept to market
- Led cross-functional teams of scientists, software engineers and engineers
- Developed and implemented automated laboratory workflows
- Successfully navigated multiple funding rounds and strategic partnerships

Industry Applications:
- Drug discovery and development
- Diagnostic platform development
- Viral vector manufacturing
- Stem cell technologies
- Vaccine development
- Recombinant protein production

Consulting Services:
- Strategic Planning
- Scientific advice
- Market entry strategy
- Technology road-mapping
- IP portfolio development
- Laboratory Operations
- Design and construction optimization
- Workflow automation